DS
ACRV icon

David Shaw’s Acrivon Therapeutics ACRV Stock Holding History

David Shaw’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-31,939
Closed -$157K – 4296
2023
Q4 		$157K Sell
31,939
-14,811
-32% -$78.2K ﹤0.01% 3918
2023
Q3 		$447K Sell
46,750
-160
-0.3% -$1.85K ﹤0.01% 3471
2023
Q2 		$608K Sell
46,910
-14,986
-24% -$181K ﹤0.01% 3340
2023
Q1 		$785K Buy
+61,896
New +$1.04M ﹤0.01% 3324

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

David Shaw's ACRV Position: Q1 2024 in Review

David Shaw sold out of Acrivon Therapeutics (ACRV) in Q1 2024, closing a stake of 31,939 shares — an estimated $157K sold.

David Shaw first reported a position in ACRV in Q1 2023 and held it in 4 quarters. The position peaked at $785K in Q1 2023. 48 funds tracked by Wall St. Rank hold ACRV as of Q1 2024.

  • David Shaw reported no remaining Acrivon Therapeutics position as of Q1 2024 after selling out during the quarter.
  • David Shaw sold 31,939 Acrivon Therapeutics shares in Q1 2024, an estimated $157K.
  • David Shaw first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 4 quarters.
  • David Shaw's Acrivon Therapeutics position peaked at $785K in Q1 2023.
  • 48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.